Clinical Trials Browser

Urachal adenocarcinoma, Urachal cancer, Fibrolamellar hepatocellular carcinoma, Secretory breast carcinoma, Carcinoma, Ovarian Epithelial, Adrenal Gland Neoplasms, Anus Neoplasms, Biliary Tract Neoplasms, Carcinosarcoma, Carcinoma, Adenoid Cystic, Fallopian Tube Neoplasms, Fibrosarcoma, Gallbladder Neoplasms, Granulosa Cell Tumor, Hemangiosarcoma, Leiomyosarcoma, Mesothelioma, Neuroblastoma, Parathyroid Neoplasms, Penile Neoplasms, Sarcoma, Sarcoma, Kaposi, Osteosarcoma, Thyroid Neoplasms, Trophoblastic Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Hepatoblastoma, Endodermal Sinus Tumor, Neuroectodermal Tumors, Primitive, Cholangiocarcinoma, Sertoli-Leydig Cell Tumor, Neurofibrosarcoma, Hemangioblastoma, Neuroendocrine Tumors

NCT02453620 2026-04-13

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

Phase 1 Active not recruiting

57 enrolled

BreastOther solid neoplasm

Anatomic Stage III Breast Cancer AJCC v8

NCT06362369 2026-04-13

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Phase 1/2 Recruiting

126 enrolled

DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Turcot syndrome, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Skin Neoplasms, Colorectal Neoplasms

NCT04665206 2026-04-02

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

Phase 1/2 Recruiting

434 enrolled

Other solid neoplasmThoracic

Mesothelioma

NCT06097728 2026-04-02

eVOLVE-Meso

Phase 3 Recruiting

825 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

Clinical Trials

ANTARES

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

eVOLVE-Meso

A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers

Metro-PD1

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours

CD8 PET Imaging in Metastatic Solid Tumours

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

CheckMate 6DW

DREAM3R

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

Trial of INI-4001 in Patients With Advanced Solid Tumours

Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies

Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors

CheckMate142

IMPALA

A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors

A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

NIPISAFE

A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors

Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)

Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors

Study of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Solid Tumors

Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma

A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors

CONFIRM

Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery

myDAvIpNi

A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors

Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

CheckMate743

Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma

PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates

ONO-4538 Phase I Study in Patients With Solid Tumor

ONO-4538 Phase I Study in Patients With Solid Tumor

A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy

NIPU

NIMBLe

RACIN

RELATIVITY-111

A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma

Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors